Clinical Trial Detail

NCT ID NCT03435250
Title Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Agios Pharmaceuticals, Inc.
Indications

pancreatic ductal adenocarcinoma

Advanced Solid Tumor

lymphoma

lung non-small cell carcinoma

Therapies

AG-270 + Docetaxel

AG-270 + Gemcitabine + Nab-paclitaxel

AG-270

Age Groups: senior adult

Additional content available in CKB BOOST